AbbVie’s ABBV stock slipped below its 50-day simple moving average (SMA) late last week. The stock has also declined by ...

AbbVie Inc. (NYSE:ABBV) is included among the 15 Best Stocks to Buy for the Long Term. On December 10, HSBC increased its ...

Lastly, AbbVie is a fantastic income stock. The company is part of the group of Dividend Kings, corporations that have ...

Healthcare stocks have lagged the broader market for the past three years, weighed down by post-COVID earnings volatility, ...

Interestingly, despite the autumn’s upward trend, November’s haul is the first in 2025 that doesn’t outweigh the ...

Discover why AbbVie (ABBV) is rated Strong Buy, with robust 2025 growth, diversified revenues, and attractive valuation.

This trial evaluated the safety and efficacy of the combination of AbbVie and Genmab’s Epkinly (epcoritamab), a CD3xCD20 ...

AbbVie remains a Strong Buy due to robust growth in immunology and neuroscience portfolios, offsetting Humira's decline.

The latest round of Medicare price cuts affect 15 drugs, including Xtandi, an older prostate cancer drug from Pfizer and Astellas Pharma Inc. that will face a 48% discount off its 2024 list price. GSK ...

Close to two years after AbbVie handed over $48 million for the rights to OSE Immunotherapeutics’ inflammation drug, the Big ...

If you are wondering whether AbbVie is still attractive after its huge run, or if you are late to the party, you are in the ...

AbbVie is seeking European approval of expanded use of its migraine drug atogepant in adults following strong results from a ...